Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 29, Issue 2, 2013, Pages 184-189

  Whelan, Kevin ^a   Quigley, Eamonn M M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

inflammatory bowel disease; irritable bowel syndrome; microbiota; probiotics

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; PLACEBO; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; BIFIDOBACTERIALES; BIFIDOBACTERIUM BIFIDUM; BLOATING; CASE CONTROL STUDY; CHRONIC INFLAMMATION; COMPARATIVE STUDY; CROHN DISEASE; ENTERITIS; GASTROINTESTINAL TRACT FUNCTION; HEALTH PRACTITIONER; HUMAN; ILEITIS; INFLAMMATION; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; META ANALYSIS; PATHOGENESIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES BOULARDII; SEPTICEMIA; SHORT BOWEL SYNDROME; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; WORLD HEALTH ORGANIZATION;

GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; METAGENOME; PROBIOTICS;

EID: 84873410287     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835d7bba     Document Type: Review

References (42)

1. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59-65.
2. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473:174-180.
3. Claesson MJ, Cusack S, O'Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108 (Suppl 1):4586-4591.
4. Shanahan F. The colonic microbiota in health and disease. Curr Opin Gastroenterol 2013; 29:49-54.
5. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334:105-108.
6. Faith JJ, McNulty NP, Rey FE, Gordon JI. Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 2011; 333:101-104.
7. FAO/WHO. FAO/WHO 'Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria'. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria (October 2001). http://www.who.int/foodsafety/publications/fs-management/en/ probiotics.pdf [Accessed 23 November 2012].
8. Sanders ME, Levy DD. The science and regulations of probiotic food and supplement product labeling. Ann N Y Acad Sci 2011; 1219 (Suppl 1):E1-E23.
9. O'Shea EF, Cotter PD, Stanton C, et al. Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: Bacteriocins and conjugated linoleic acid. Int J Food Microbiol 2012; 152:189-205.
10. Sanders ME, Akkermans LM, Haller D, et al. Safety assessment of probiotics for human use. Gut Microbes 2010; 1:164-185.
11. Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics to reduce risk and prevent or treat disease. Evidence Report/Technology Assessment No. 200 (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290-2007-10062-I). AHRQ Publication No. 11-E007. Rockville, MD: Agency for Healthcare Research and Quality; April 2011. http://www. ahrq.gov/downloads/pub/evidence/pdf/probiotics/probiotics.pdf [Accessed 23 November 2012].
12. Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: A systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr 2010; 91:687-703.
13. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebocontrolled trial. Lancet 2008; 371:651-659.
14. Konieczna P, Akdis CA, Quigley EM, et al. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes 2012; 3:261-266.
15. Chang JY, Talley NJ. An update on irritable bowel syndrome: from diagnosis to emerging therapies. Curr Opin Gastroenterol 2011; 27:72-78.
16. Porter CK, Gormley R, Tribble DR, et al. The incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol 2011; 106:130-138.
17. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut 2013; 62:159-176.
18. Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 2012; 24:31-39.
19. Brint EK, MacSharry J, Fanning A, et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106:329-336.
20. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: A review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011; 14:581-587.
21. Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev 2009:CD003019.
22. National Institute for Health and Clinical Excellence (NICE). Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. London, UK: National Collaborating Centre for Nursing and Supportive Care; 2008.
23. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am J Gastroenterol 2009; 104:1033-1049.
24. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. Gut 2010; 59:325-332.
25. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14:2650-2661.
26. Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and metaanalysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9:15.
27. McKenzie YA, Alder A, Anderson W, et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012; 25:260-274.
28. Guglielmetti S, Mora D, Gschwender M, et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life Y a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33:1123-1132.
29. Kruis W, Chrubasik S, Boehm S, et al. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27:467-474.
30. Mercer M, Brinich MA, Geller G, et al. How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome. J Clin Gastroenterol 2012; 46:138-144.
31. Brant SR. Promises, delivery, and challenges of inflammatory bowel disease risk gene discovery. Clin Gastroenterol Hepatol 2013; 11:22-26.
32. Benjamin JL, Hedin CR, Koutsoumpas A, et al. Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 2012; 18:1092-1100.
33. Li E, Hamm CM, Gulati AS, et al. Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One 2012; 7:e26284.
34. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15:1183-1189.
35. Konieczna P, Groeger D, Ziegler M, et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 2012; 61:354-366.
36. Grangette C, Nutten S, Palumbo E, et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Nat Acad Sci USA 2005; 102:10321-10326.
37. Yan F, Cao H, Cover TL, et al. Colon-specific delivery of a probioticderived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 2011; 121:2242-2253.
38. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010:CD001176.
39. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: A systematic review of intervention studies in adult patients. Drugs 2012; 72:803-823.
40. Oliva S, Di NardoG, Ferrari F, et al. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012; 35:327-334.
41. Tursi A, BrandimarteG, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105:2218-2227.
42. Hedin CR, Mullard M, Sharratt E, et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: A case-control study. Inflamm Bowel Dis 2010; 16:2099-2108.